• Profile
Close

Substantial gaps in evaluation and treatment of patients with hepatitis B in the US

Journal of Hepatology Sep 06, 2021

Ye Q, Kam LY, Hui Y, et al. - The findings revealed that in the US, half of chronic hepatitis B virus (HBV) infection patients with private insurance did not have a complete laboratory assessment. Antiviral therapy was not received by over one-third of treatment-eligible patients. The results showed that individuals who visited a GI/ID specialist had a higher chance of receiving adequate evaluation and treatment. There is a need for urgent intervention to distinguish and address the barriers to these care gaps.

  • Researchers recruited a total of 12,608 eligible patients in the study analysis (mean age 45.7 years, 52.1% male, 54.6% Asian, 18.1% Caucasian, 10.5% African American).

  • The data indicated that about half of the cohort (n=6,559, 52.3%) did not have a complete laboratory evaluation (defined as having HBeAg, HBV DNA, and ALT tests) and only 72.4% (n=9,129) had an “adequate” evaluation (at least HBV DNA and ALT) during the entire study period.

  • Among those with an adequate evaluation, 11.2% were treatment eligible by AASLD criteria and 13.9% by EASL criteria; and of these, 60.4% of AASLD eligible patients and 54.3% of EASL eligible patients received treatment within 12 months from becoming eligible.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay